A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model

Gliomas are the second most common primary brain tumors in adults. They are treated with combination therapies, including surgery, radiotherapy, and chemotherapy. There are currently limited treatment options for recurrent gliomas, and new targeted therapies need to be identified, especially in glio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2020-02, Vol.19 (2), p.375-383
Hauptverfasser:	Machida, Yukino, Nakagawa, Makoto, Matsunaga, Hironori, Yamaguchi, Masayuki, Ogawara, Yoko, Shima, Yutaka, Yamagata, Kazutsune, Katsumoto, Takuo, Hattori, Ayuna, Itoh, Masato, Seki, Takahiko, Nishiya, Yumi, Nakamura, Koichi, Suzuki, Kanae, Imaoka, Tomoki, Baba, Daichi, Suzuki, Makoto, Sampetrean, Oltea, Saya, Hideyuki, Ichimura, Koichi, Kitabayashi, Issay
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Animals Blood-Brain Barrier - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - enzymology Brain Neoplasms - pathology Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - pharmacology Glioblastoma - drug therapy Glioblastoma - enzymology Glioblastoma - pathology Humans Isocitrate Dehydrogenase - antagonists & inhibitors Isocitrate Dehydrogenase - genetics Isocitrate Dehydrogenase - metabolism Isoxazoles - chemistry Isoxazoles - pharmacokinetics Isoxazoles - pharmacology Male Mice Mice, Inbred NOD Mice, SCID Mutation Random Allocation Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!